Stay updated on ONO-4538 in NSCLC Clinical Trial
Sign up to get notified when there's something new on the ONO-4538 in NSCLC Clinical Trial page.

Latest updates to the ONO-4538 in NSCLC Clinical Trial page
- Check2 days agoChange DetectedSite revision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check9 days agoChange DetectedA new plain-language TASUKI-52 publication (Future Oncol. 2026; Sugawara et al.) was added. The earlier online-ahead-of-print entry for this publication was removed.SummaryDifference0.0%

- Check16 days agoNo Change Detected
- Check24 days agoNo Change Detected
- Check38 days agoChange DetectedThe page now includes a plain language summary for TASUKI-52 describing nivolumab plus platinum chemotherapy and bevacizumab for NSCLC, and the revision was updated to v3.4.2. A government funding notice was removed.SummaryDifference0.2%

- Check45 days agoChange DetectedAdded a government funding/status notice and a new 2026 publication citation for TASUKI-52. The page revision tag shows v3.4.1, replacing v3.4.0.SummaryDifference0.2%

- Check52 days agoChange DetectedGlossary display was added, and new metadata entries 'Last Update Submitted that Met QC Criteria' and 'Revision: v3.4.0' along with a 'No FEAR Act Data' note were introduced. The older labels 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4' were removed.SummaryDifference0.1%

- Check67 days agoChange DetectedRevision updated: added v3.3.4 and removed v3.3.3.SummaryDifference0.0%

Stay in the know with updates to ONO-4538 in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ONO-4538 in NSCLC Clinical Trial page.